Immunogenicity and safety of virus-like particle of the porcine encephalomyocarditis virus in pig

Jeoung, Hye-Young; Lee, Won‐Ha; Jeong, Wooseog; Shin, Bo-Hye; Choi, Hwan-Won; Lee, Hee Soo; An, Dong-Jun

doi:10.1186/1743-422x-8-170

Cited by 29 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, a prime-boost strategy was more effective than a single-dose immunization, in inducing the production and maintenance of neutralizing antibodies. 113…”

Section: Picornaviridaementioning

confidence: 99%

Virus-like particle-based vaccines for animal viral infections

Crisci

Bárcena²,

Montoya

2013

Inmunología

View full text Add to dashboard Cite

i n m u n o l o g í a . 2 0 1 3;3 2(3):102-116 103Por lo general son antigénicamente indistinguibles de los virus de los que proceden y su empleo como inmunógenos presenta importantes ventajas en términos de seguridad. Las VLPs pueden inducir una fuerte respuesta inmune, tanto humoral como celular, y se ha demostrado que poseen capacidad de actuar como adyuvantes (self-adjuvanting). Además de su idoneidad como vacunas frente al virus homólogo del cual proceden, las VLPs también se pueden utilizar como vectores para la presentación multimérica de antígenos heterólogos. Las VLPs han mostrado una elevada eficacia como candidatos vacunales, sin embargo, hasta el momento sólo una vacuna basada en VLPs ha sido autorizada y comercializada en el campo veterinario. En este trabajo se revisa el estado actual de las VLP empleadas como nuevas estrategias vacunales en el campo de la veterinaria, analizando las potenciales ventajas y desafíos que enfrenta esta tecnología.

show abstract

“…In this study, a prime-boost strategy was more effective than a single-dose immunization, in inducing the production and maintenance of neutralizing antibodies. 113…”

Section: Picornaviridaementioning

confidence: 99%

Virus-like particle-based vaccines for animal viral infections

Crisci

Bárcena²,

Montoya

2013

Inmunología

View full text Add to dashboard Cite

show abstract

“…The immunization elicited neutralizing antibody levels similar to those obtained after administration of the commercial vaccine. In this study, a prime-boost strategy was more effective than a single-dose immunization, in inducing the production and maintenance of neutralizing antibodies (Jeoung et al, 2011).…”

Section: Animal Virus Vlps As Vaccine Immunogensmentioning

confidence: 77%

Virus-like particles: The new frontier of vaccines for animal viral infections

Crisci

Bárcena²,

Montoya

2012

Veterinary Immunology and Immunopathology

137

116

View full text Add to dashboard Cite

Vaccination continues to be the main approach to protect animals from infectious diseases. Until recently, all licensed vaccines were developed using conventional technologies. Subunit vaccines are, however, gaining attention from researchers in the field of veterinary vaccinology, and among these, virus-like particles (VLPs) represent one of the most appealing approaches. VLPs are robust protein cages in the nanometer range that mimic the overall structure of the native virions but lack the viral genome. They are often antigenically indistinguishable from the virus from which they were derived and present important advantages in terms of safety. VLPs can stimulate strong humoral and cellular immune responses and have been shown to exhibit self-adjuvanting abilities. In addition to their suitability as a vaccine for the homologous virus from which they are derived, VLPs can also be used as vectors for the multimeric presentation of foreign antigens. VLPs have therefore shown dramatic effectiveness as candidate vaccines. Here, we review the current status of VLPs as a vaccine technology in the veterinary field, and discuss the potential advantages and challenges of this technology.

show abstract

“…In current study, for first time, we improved a novel strategy to produce HPV VLP using stably transfected Leishmania cells. We could transfect immunization with crude protein containing the VLPs led to 90% protection from EMCV infection [17]. In addition, immunization of BALB/c mice with EV71 VLP elicited potent and long-lasting humoral immune responses as shown by the high total IgG titer [18].…”

Section: Discussionmentioning

confidence: 98%